In Germany, the forecasted sales for non-steroids anti-inflammatory and antirheumatic medicines per capita are projected to increase marginally from 2024 to 2028, starting at an estimated value of $8.3 in 2024 and reaching $8.5 by 2028. This indicates a negligible compound annual growth rate (CAGR) over this 5-year forecast period. Year-on-year changes suggest a stable market environment with minimal fluctuations in consumer demand or price adjustments between 2024 and 2028.
Future trends to watch include innovations in drug formulations, potential regulatory changes in healthcare policies, and shifts in consumer preferences toward alternative therapies, which may influence market dynamics and growth rates in the anti-inflammatory medicine sector over the medium to long term.
